CYP19A1 and breast carcinoma: Moreover, a recent study indicated that the lncRNA LINC00309 is associated with poor disease-free survival in patients with breast cancer treated with endocrine therapy using aromatase inhibitors, which suggests that LINC00309 plays important roles in the acquisition of resistance to these therapeutic agents [101].